U.S. Markets close in 3 hrs 34 mins

Wired News - Halyard Health to Buy CoolSystems; Marketed as Game Ready(R)

Stock Monitor: CAS Medical Systems Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want access to our free research report on Halyard Health, Inc. (NYSE: HYH), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=HYH as the Company's latest news hit the wire. On June 05, 2018, the Company announced that it has inked a deal to acquire CoolSystems, Inc., marketed as Game Ready®, a market-leading provider of cold therapy and compression therapy systems for a total consideration of $65 million in cash. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for CAS Medical Systems, Inc. (NASDAQ: CASM), which also belongs to the Healthcare sector as the Company Halyard Health. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Halyard Health most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Acquisition Details

Halyard will fund the acquisition from current cash. The transaction is expected to close early in Q3 2018. The transaction is expected to be immaterial to Halyard's fiscal year 2018 adjusted dilutive net earnings per share, and slightly accretive to earnings in 2019. Halyard is reaffirming its 2018 adjusted dilutive net earnings per share guidance of $1.65 to $1.85, which includes earnings from both continuing and discontinued operations.

Combination of Game Ready's Cold Therapy Products with Halyard's ON-Q* Pain Relief System Portfolio will Enhance Halyard's Postoperative Non-Opioid Product Offerings

Joe Woody, CEO of Halyard, stated that the acquisition of Game Ready represents another step forward in Halyard's transformation as a pure-play medical device company and is consistent with the Company's strategy to continually generate value for its patients, customers, and shareholders.

Joe added that the combination of Game Ready's market leading cold therapy products with Halyard's ON-Q* Pain Relief System portfolio will significantly enhance the Company's postoperative non-opioid product offerings and broaden its orthopedic footprint.

According to him, combined, both companies will be better positioned to play a critical role in providing innovative non-opioid therapies that reduce or eliminate the use of opioids for surgical patients and get them back to the things that matter.

Halyard Completed Divestiture of its S&IP Business to Owens & Minor

On May 01, 2018, the Company completed the previously disclosed divestiture of its S&IP business to Owens and Minor, Inc. for $710 million, subject to certain adjustments as provided in the Amended and Restated Purchase Agreement. The divestiture of S&IP transformed Halyard into a focused, pure-play medical devices business with a clear playbook for solid revenue and earnings growth. The Company intends to use the approximately $600 million in net proceeds from the sale to pay off its existing Term Loan B credit facility and to fund internal investment and M&A.

Halyard Changes its Name to Avanos Medical, Inc.

On June 01, 2018, Halyard announced the business rebrand to Avanos Medical, Inc. The new name and brand emphasize the Company's focus on innovating with speed to deliver better, more sustainable patient outcomes. The change in name from Halyard to Avanos will be effective June 30, 2018. In connection with this rebrand, the Company's stock ticker symbol will change from "HYH" to "AVNS" on the New York Stock Exchange. The first day of trading under the new ticker symbol will be July 02, 2018.

About CoolSystems, Inc. (Game Ready)

Game Ready develops, manufactures, and markets the Game Ready® product line, used in the pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries. Its product-line includes GRPro® 2.1 cold and compression therapy system; Med4 Elite™ multi-modality therapy unit; ATX® Wraps; and a variety of product accessories, all of which complement Halyard's existing Pain Management portfolio.

About Halyard Health, Inc.

Headquartered in Alpharetta, Georgia, Halyard Health is a medical technology company focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company delivers clinically-superior products and solutions in infection prevention, surgical solutions, respiratory health, digestive health, pain management, and IV therapy.

Stock Performance Snapshot

June 06, 2018 - At Wednesday's closing bell, Halyard Health's stock slightly rose 0.22%, ending the trading session at $58.63.

Volume traded for the day: 467.21 thousand shares, which was above the 3-month average volume of 457.32 thousand shares.

Stock performance in the last month - up 10.83%; previous three-month period - up 23.72%; past twelve-month period - up 60.85%; and year-to-date - up 26.96%

After yesterday's close, Halyard Health's market cap was at $2.75 billion.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 1.0% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors